Lunai Bioworks Inc.
For the period ended Jun 30, 2026. Filed Oct 13, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2026 · Filed Oct 13, 2026
LNAI$0.16-30.2%Stored close · as of Oct 29, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits, Financial Statement Schedules
| Exhibit No. | Description | Incorporated by Reference |
| 2.1 | Agreement and Plan of Merger, dated February 26, 2025, by and among Renovaro, Inc., Renovaro Acquisition Sub and BioSymetrics, Inc. | Incorporated by reference to Exhibit 2.1 to the Company’s Form 8-K filed with the SEC on February 28, 2025. |
| 2.2 | Second Amendment to Stock Purchase Agreement, dated February 13, 2024, by and among Lunai Bioworks Inc., GEDi Cube Intl Ltd., the sellers party thereto and Yalla Yalla Ltd | Incorporated by reference to Exhibit 2.1 to the Company’s Form 8-K filed with the SEC on February 14, 2024 |
| 2.3† | Agreement and Plan of Merger, dated April 27, 2026, by and among Lunai Bioworks, Inc., Lunai Bioworks IP, Inc., Neurobridge IP Holdings Incorporated, Oncotelic Inc. and Pelerin Therapeutics Inc. | Incorporated herein by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed with the SEC on May 5, 2026 |
| 3.1 | Certificate of Incorporation, as amended | Incorporated by reference to Exhibit 3.1 to the Company’s Form 10-Q filed with the SEC on February 14, 2024 |
| 3.2 | Amended and Restated Bylaws | Incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on May 21, 2024. |
| 3.3 | Certificate of Amendment to the Restated Certificate of Incorporation of Renovaro Inc., dated August 18, 2025 (Name Change). | Incorporated by reference to Exhibit 3.1 to the Company’s Form 8-K filed with the SEC on August 26, 2025. |
| 3.4 | Certificate of Amendment to the Restated Certificate of Incorporation (1-for-10 Reverse Stock Split), dated September 18, 2025 | Incorporated herein by reference to Exhibit 3.1 to the Company’s Form 8-K filed with the SEC on September 24, 2025 |
| 3.5 | Certificate of Designation of Series B Convertible Preferred Stock, filed with the Secretary of State of the State of Delaware on May 1, 2026 | Incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on May 5, 2026 |
| 3.6 | Certificate of Amendment to the Certificate of Incorporation of Lunai Bioworks Inc., filed with the Secretary of State of the State of Delaware on May 20, 2026 and effective May 22, 2026* | Filed herewith |
| 4.1 | Registration Rights Agreement, dated February 13, 2024, by and among Lunai Bioworks Inc. GEDi Cube Intl Ltd, and the shareholders of GEDi Cube Intl Ltd named the Sellers named thereto | Incorporated herein by reference to exhibit to the Company’s Form 8-K filed with the SEC on February 14, 2024 |
| 4.2 | Promissory Note dated March 30, 2020 issued to Paseco ApS | Incorporated herein by reference to Exhibit 10.2 to the Company’s Form 8-K filed with the SEC on March 31, 2020. |
| 4.3 | Amendment No.2 to Promissory Note, dated May 17, 2022 | Incorporated herein by reference to Exhibit 4.3 to the Company’s Form 10-K filed with the SEC on February 27, 2023. |
| 4.4 | Amendment No.3 to Promissory Note, effective December 30, 2022 | Incorporated herein by reference to Exhibit 10.2 to the Company’s Form 8-K filed with the SEC on February 23, 2023. |
| 4.5 | Amendment No. 4 to Promissory Note, effective July 31, 2023 | Incorporated by reference to Exhibit 10.2 to the Company’s Form 8-K filed with the SEC on August 7, 2023 |
| 4.6 | Description of Securities | Filed herewith’ |
| 4.7 | Form of Warrant | Incorporated by reference to Exhibit 4.1 to the Company’s Form 8-K filed with the SEC on April 3, 2023 |
| 4.8 | Form of Warrant | Incorporated by reference to Exhibit 4.1 to the Company’s Form 8-K filed with the SEC on August 7, 2023 |
| 4.9 | Form of Warrant | Incorporated herein by reference to Exhibit 4.1 to the Company’s Form 8-K filed with the SEC on June 21, 2024 |
| 4.10 | Form of 5% Original Issue Discount Convertible Promissory Note | Incorporated herein by reference to Exhibit 4.1 to the Company’s Form 8-K filed with the SEC on October 10, 2023 |
| 4.11 | Form of Convertible Note | Incorporated herein by reference to Exhibit 99.2 to the Company’s Form 8-K filed with the SEC on July 9, 2025 |
| 4.12 | Form of Common Stock Purchase Warrant issued pursuant to the Debt Exchange Agreements, dated March 24, 2026 | Incorporated herein by reference to Exhibit 4.1 to the Company’s Form 8-K filed with the SEC on March 30, 2026 |
| 10.1 | 2019 Equity Incentive Plan | Incorporated herein by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on February 10, 2020. |
| 10.2 | 2023 Equity Incentive Plan | Incorporated herein by reference to Exhibit 10.12 to the Company’s Form 10-K/A filed with the SEC on October 30, 2023 |
| 10.3 | Statement of Work and License Agreement by and among G-Tech Bio, LLC, the Company and G Health Research Foundation | Incorporated herein by reference to Exhibit 10.1 to the Company’s Form 8-K filed with the SEC on February 3, 2020. |
| 10.4 | Note Purchase Agreement | Incorporated herein by reference to Exhibit 10.1 to the Company’s Form 8-K filed with the SEC on March 31, 2020. |
| 10.5 | General Office Lease by and between the Registrant and Century City Medical Plaza Land Co., Inc. dated June 19, 2018 | Incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the SEC on June 25, 2018. |
| 10.6 | Employment Agreement, dated August 11, 2021, by and between the Company and Dr. Mark Dybul | Incorporated herein by reference to Exhibit to 10.1 the Company’s Current Report on Form 8-K/A, filed with the SEC on August 16, 2021. |
| 10.7 | Amendment to Employment Agreement between Mark Dybul, M.D. and the Company, dated December 12, 2022 | Incorporated herein by reference to Exhibit to 10.1 the Company’s Current Report on Form 8-K, filed with the SEC on December 16, 2022. |
| 10.10 | Security Agreement, effective December 30, 2022, by and between the Company and Paseco ApS | Incorporated herein by reference to Exhibit 10.2 to the Company’s Form 8-K filed with the SEC on February 23, 2023. |
| 10.11 | Purchase Agreement, dated June 20, 2023, by and between the Company and Lincoln Park Capital Fund, LLC | Incorporated herein by reference to Exhibit 10.1 to the Company’s Form 8-K filed with the SEC on June 27, 2023 |
| 10.12 | Registration Rights Agreement, dated June 20, 2023, by and between the Company and Lincoln Park Capital Fund, LLC | Incorporated herein by reference to Exhibit 10.2 to the Company’s Form 8-K filed with the SEC on June 27, 2023 |
| 10.13 | Consulting Agreement, dated March 11, 2024, by and between Lunai Bioworks Inc. and Tarsh PB Advisors LLC. | Incorporated herein by reference to Exhibit 10.1 to the Company’s Form 8-K filed with the SEC on March 13, 2024 |
| 10.14 | Form of Subscription Agreement | Incorporated herein by reference to Exhibit 10.1 to the Company’s Form 8-K filed with the SEC on August 7, 2023 |
| 10.15 | Form of Subscription Agreement | Incorporated herein by reference to Exhibit 10.1 to the Company’s Form 8-K filed with the SEC on October 10, 2023 |
| 10.16 | Form of Subscription Agreement | Incorporated herein by reference to Exhibit 10.1 to the Company’s Form 8-K filed with the SEC on June 21, 2024 |
| 10.17 | Form of Exchange Agreement | Incorporated herein by reference to Exhibit 99.1 to the Company’s Form 8-K filed with the SEC on July 9, 2025 |
| 10.18 | Form of Debt Exchange Agreement, dated March 24, 2026, between the Company and the holders party thereto | Incorporated herein by reference to Exhibit 10.1 to the Company’s Form 8-K filed with the SEC on March 30, 2026 |
| 10.19 | At-the-Market Sales Agreement, dated December 2, 2025, between Lunai Bioworks, Inc. and Dawson James Securities, Inc. | Incorporated herein by reference to Exhibit 1.1 to the Company’s Current Report on Form 8-K filed with the SEC on December 3, 2025. |
| 10.20+ | First Amendment to the Renovaro BioSciences Inc. 2023 Equity Incentive Plan, adopted October 12, 2025 | Incorporated herein by reference to Annex A to the Company’s Definitive Proxy Statement filed with the SEC on October 16, 2025. |
| 10.21* | Debt Conversion and Share Issuance Agreement, dated July 21, 2026, by and among Lunai Bioworks Inc. and the creditors party thereto | Filed herewith |
| 10.22* | Master Consulting and Strategic Advisory Agreement, dated September 2, 2026, between the Company and Strategic Advisors S.à r.l. | Filed herewith |
| 19.1* | Lunai Bioworks Inc. Insider Trading Policy (within CORPORATE CODE OF ETHICS AND CONDUCT POLICY) | Filed herewith |
| 21.1* | Subsidiaries of the Registrant | Filed herewith |
| 23.1* | Consent of Sadler, Gibb & Associates | |
| 31.1* | Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934 | |
| 31.2* | Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934 | |
| 32.1** | Certification of Principal Executive Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350 | |
| 32.2** | Certification of Chief Financial Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350 | |
| 97.1 | Clawback Policy | Incorporated herein by reference to Exhibit 97.1 to the Company’s Form 10-K filed with the SEC on October 10, 2024 |
| 101.INS | XBRL Instance Document* | |
| 101.SCH | XBRL Taxonomy Extension Schema* | |
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase* | |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase* | |
| 101.LAB | XBRL Taxonomy Extension Label Linkbase* | |
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase* | |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) * |
| * | Filed herewith. |
|---|---|
| ** | Furnished herewith. |
| + | Indicates a management contract or compensatory plan or arrangement. |
| † | Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.